GlobeNewsWire
15 Oct 2025, 13:15 UTC · 49w ago
Verdict
Headline takes no side. We score ARTL +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 85% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Interim Phase 2 data for ART27.13 showed treated cancer patients gained over 6% in weight compared to a 5% loss in the placebo group.
So whatPositive Phase 2 efficacy data for a treatment targeting a high-unmet-need market (cancer anorexia) is a major valuation driver for clinical-stage biotech.
More positive than 99% of claims this week
Phase 1 data for ART26.12 demonstrated the drug was safe and well-tolerated at single doses up to 1050 milligrams with predictable linear plasma exposure.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 77% of claims this week
ART27.13 is currently the most clinically advanced small-molecule, orally administered once-daily treatment for cancer anorexia, with no approved treatments currently in the US, UK, or EU.
More positive than 63% of claims this week
Which stocks this story touches
More positive than 85% of ticker scores this week
The company reported positive Phase 1 safety data for ART26.12 and substantial weight gain/activity improvements in Phase 2 interim data for ART27.13.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
17h ago
−65.6%
Price is moving against the score
$12.83 vs $37.26 close before publication (Oct 14) · not market-adjusted
ARTL chart →